Contacts
  • Increase
  • Decrease
  • Normal

Search form

Accessibility

From genes to therapy

GMP Solutions

MolMed GMP Solutions provides tailor-made services for your cell & gene therapy projects.

Read

Investor kit

MolMed online Investor kit delivers all the financial documents and usefull tools to monitor the share performance. To order printed materials, or request additional investor-related information, complete the Investor contact form.

Download

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.

Products of excellence

NGR-hTNF
Today status

TK
Today status
Scientific stuff

Publications

Poster
Impact of treatment free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM)
Poster
Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy
Poster
Randomized phase II trial of NGR-hTNF with an anthracycline in platinum refractory or resistant ovarian cancer (OC)
Read all

Last presentation

Mar 10, 2014 - Mar 12, 2014
BioEurope Spring 2014, Torino (Italy)
Company presentation at Bio-Europe Spring 2014
Download
201420132012
All presentations

Financial reports

Annual financial report (English translation for convenience) 2013
Annual financial report (English translation for convenience)
Download
Half-year financial report (in Italian) at 06/30/2014
Download
Interim financial report (in Italian) at 03/31/2014
Download
Quarterly financial report (in Italian) at 09/30/2013
Download
201320122011
All financial reports

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 10,874,215.42 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159